ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation

Breast Cancer Research

Volumn 12, Issue 1, 2010, Pages

  Liu, Bin ^a   Han, Mei ^a   Sun, Rong Hua ^a   Wang, Jun Jie ^a   Zhang, Yan Ping ^a   Zhang, Di Qun ^a   Wen, Jin Kun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 [5 (ETHYLPEROXY) PENTAN 2 YL] 6 METHYL 3 METHYLENE 2 OXO 2,3,3A,4,7,7A HEXAHYDROBENZOFURAN 4 YL 2 (6 METHOXYNAPHTHALEN 2 YL) PROPANOATE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CARBOBENZOXYVALYLALANYLASPARTYL (O METHYL) FLUOROMETHYLKETONE; CASPASE 3; CASPASE INHIBITOR; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 5 (5 (ETHYLPEROXY)PENTAN 2 YL) 6 METHYL 3 METHYLENE 2 OXO 2,3,3A,4,7,7A HEXAHYDROBENZOFURAN 4 YL 2 (6 METHOXYNAPHTHALEN 2 YL)PROPANOATE; 5-(5-(ETHYLPEROXY)PENTAN-2-YL)-6-METHYL-3-METHYLENE-2-OXO-2,3,3A,4,7,7A-HEXAHYDROBENZOFURAN-4-YL 2-(6-METHOXYNAPHTHALEN-2-YL)PROPANOATE; ACETYLBRITANNILATONE; CASPASE; LACTONE; NAPHTHALENE DERIVATIVE; SESQUITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA FLANKING REGION; DRUG ANTAGONISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL CYCLE; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LACTONES; MICE; MICE, INBRED BALB C; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; SESQUITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956047913     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2475     Document Type: Article

References (52)

1. Mellstedt H. Cancer initiatives in developing countries. Ann Oncol 2006, 17:viii24-viii31. 10.1093/annonc/mdl984, 16801336.
2. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005, 34:405-412. 10.1093/ije/dyh414, 15737977.
3. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 2005, 4:1277-1285. 10.1158/1535-7163.MCT-05-0027, 16093444.
4. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002, 8:641-661.
5. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014. 10.1056/NEJM199504133321507, 7885406.
6. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH, Li-Weber M. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer 2007, 121:1839-1846. 10.1002/ijc.22883, 17565740.
7. Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 2007, 13:1298-1307. 10.1158/1078-0432.CCR-06-1277, 17287296.
8. Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007, 13:1269-1277. 10.1158/1078-0432.CCR-06-1839, 17317839.
9. Liu J, Zhou W, Li SS, Sun Z, Lin B, Lang YY, He JY, Cao X, Yan T, Wang L, Lu J, Han YH, Cao Y, Zhang XK, Zeng JZ. Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues. Cancer Res 2008, 68:8871-8880. 2679687, 18974131, 10.1158/0008-5472.CAN-08-1972.
10. Wang Z, Qiu J, Guo TB, Liu A, Wang Y, Li Y, Zhang JZ. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 2007, 179:5958-5965.
11. Zhang M, Huang J, Xie X, Holman CD. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer 2009, 124:1404-1408. 10.1002/ijc.24047, 19048616.
12. Razis ED, Fountzilas G. Paclitaxel: epirubicin in metastatic breast cancer--a review. Ann Oncol 2001, 12:593-598. 10.1023/A:1011108807105, 11432615.
13. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995, 6:325-341.
14. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991, 51:2212-2222.
15. Liu B, Han M, Wen JK. Acetylbritannilactone Inhibits neointimal hyperplasia after balloon injury of rat artery by suppressing nuclear factor-kappa B activation. J Pharmacol Exp Ther 2008, 324:292-298. 10.1124/jpet.107.127407, 17911374.
16. Liu YP, Wen JK, Zheng B, Zhang DQ, Han M. Acetylbritannilactone suppresses lipopolysaccharide-induced vascular smooth muscle cell inflammatory response. Eur J Pharmacol 2007, 577:28-34. 10.1016/j.ejphar.2007.08.030, 17915214.
17. Bai N, Lai CS, He K, Zhou Z, Zhang L, Quan Z, Zhu N, Zheng QY, Pan MH, Ho CT. Sesquiterpene lactones from Inula britannica and their cytotoxic and apoptotic effects on human cancer cell lines. J Nat Prod 2006, 69:531-535. 10.1021/np050437q, 16643020.
18. Rafi MM, Bai NS, Chi Tang H, Rosen RT, White E, Perez D, Dipaola RS. A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res 2005, 25:313-318.
19. Park EJ, Kim J. Cytotoxic sesquiterpene lactones from Inula britannica. Planta Med 1998, 64:752-754. 10.1055/s-2006-957573, 9933993.
20. Easty GC, Easty DM, Monaghan P, Ormerod MG, Neville AM. Preparation and identification of human breast epithelial cells in culture. Int J Cancer 1980, 26:577-584. 10.1002/ijc.2910260509, 6263809.
21. Edwards PA, Brooks IM, Bunnage HJ, Foster AV, Ellison ML, O'Hare MJ. Clonal analysis of expression of epithelial antigens in cultures of normal human breast. J Cell Sci 1986, 80:91-101.
22. Adhami VM, Aziz MH, Mukhtar H, Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003, 9:3176-3182.
23. Han M, Wen JK, Zheng B, Cheng Y, Zhang C. Serum deprivation results in redifferentiation of human umbilical vascular smooth muscle cells. Am J Physiol Cell Physiol 2006, 291:C50-58. 10.1152/ajpcell.00524.2005, 16467401.
24. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495. 10.1093/carcin/21.3.485, 10688869.
25. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001, 61:3062-3070.
26. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53:3976-3985.
27. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516. 2117903, 17562483, 10.1080/01926230701320337.
28. Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003, 116:4053-4056. 10.1242/jcs.00754, 12972498.
29. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656. 10.1038/nrc883, 12209154.
30. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849. 10.1038/sj.onc.1207556, 15077147.
31. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
32. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331. 10.1126/science.270.5240.1326, 7481820.
33. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326. 10.1126/science.281.5381.1322, 9735050.
34. Tafani M, Schneider TG, Pastorino JG, Farber JL. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol 2000, 156:2111-2121. 1850093, 10854232.
35. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997, 139:1281-1292. 2140220, 9382873, 10.1083/jcb.139.5.1281.
36. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
37. Hunot S, Flavell RA. Apoptosis. Death of a monopoly?. Science 2001, 292:865-866. 10.1126/science.1060885, 11341280.
38. Nicholson DW, Thornberry NA. Apoptosis. Life and death decisions. Science 2003, 299:214-215. 10.1126/science.1081274, 12522239.
39. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360. 10.1074/jbc.273.16.9357, 9545256.
40. Piwocka K, Bielak-Mijewska A, Sikora E. Curcumin induces caspase-3-independent apoptosis in human multidrug-resistant cells. Ann N Y Acad Sci 2002, 973:250-254. 10.1111/j.1749-6632.2002.tb04643.x, 12485871.
41. Heerdt BG, Houston MA, Anthony GM, Augenlicht LH. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res 1999, 59:1584-1591.
42. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999, 33:29-55. 10.1146/annurev.genet.33.1.29, 10690403.
43. Liu B, Han M, Wen JK, Wang L. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007, 250:168-176. 10.1016/j.canlet.2006.09.024, 17218055.
44. Wang L, Zhang Q, Liu B, Han M, Shan B. Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther 2008, 7:3661-3669. 10.1158/1535-7163.MCT-08-0480, 19074843.
45. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24:1199-1208. 10.1093/carcin/bgg082, 12807727.
46. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26:958-967. 10.1093/carcin/bgi040, 15705601.
47. Park C, Jin CY, Kim GY, Choi IW, Kwon TK, Choi BT, Lee SJ, Lee WH, Choi YH. Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol Appl Pharmacol 2008, 227:219-228. 10.1016/j.taap.2007.10.003, 18031783.
48. Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Wong AJ. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 2003, 63:250-255.
49. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870-874. 10.1126/science.288.5467.870, 10797012.
50. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 1998, 273:2817-2822. 10.1074/jbc.273.5.2817, 9446590.
51. Neumann-Haefelin E, Qi W, Finkbeiner E, Walz G, Baumeister R, Hertweck M. SHC-1/p52Shc targets the insulin/IGF-1 and JNK signaling pathways to modulate life span and stress response in C. elegans. Genes Dev 2008, 22:2721-2735. 2559911, 18832074, 10.1101/gad.478408.
52. Kasper B, Brandt E, Ernst M, Petersen F. Neutrophil adhesion to endothelial cells induced by platelet factor 4 requires sequential activation of Ras, Syk, and JNK MAP kinases. Blood 2006, 107:1768-1775. 10.1182/blood-2005-06-2501, 16263791.